146 related articles for article (PubMed ID: 29155972)
1. Screening Guideline for Cervical Cancer Recommends Against Human Papillomavirus-Pap Cotesting.
Azvolinsky A
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29155972
[No Abstract] [Full Text] [Related]
2. Clinical practice. Cervical-cancer screening with human papillomavirus and cytologic cotesting.
Schiffman M; Solomon D
N Engl J Med; 2013 Dec; 369(24):2324-31. PubMed ID: 24328466
[No Abstract] [Full Text] [Related]
3. The next generation of cervical cancer screening programs: Making the case for risk-based guidelines.
Perkins RB; Schiffman M; Guido RS
Curr Probl Cancer; 2018 Sep; 42(5):521-526. PubMed ID: 30146347
[No Abstract] [Full Text] [Related]
4. 2013 statement on human papillomavirus [corrected] test utilization.
Davis Davey D; Goulart R; Nayar R;
Acta Cytol; 2014; 58(2):113-6. PubMed ID: 24525558
[TBL] [Abstract][Full Text] [Related]
5. 2013 statement on human papillomavirus test utilization [corrected].
Davis Davey D; Goulart R; Nayar R;
Diagn Cytopathol; 2014 May; 42(5):449-52. PubMed ID: 24700624
[No Abstract] [Full Text] [Related]
6. [Guidelines for HPV screening should be reconsidered].
Fröberg M; Östensson E; Alder S; Andersson S
Lakartidningen; 2015 Dec; 112():. PubMed ID: 26625108
[No Abstract] [Full Text] [Related]
7. The rationale for implementation of HPV testing in routine cervical screening in Romania.
Iancu LS; Ursu RG
Rev Med Chir Soc Med Nat Iasi; 2013; 117(2):293-6. PubMed ID: 24340506
[No Abstract] [Full Text] [Related]
8. Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening in the United States: Is It Time?
Flanagan MB
Arch Pathol Lab Med; 2018 Jun; 142(6):688-692. PubMed ID: 29848034
[TBL] [Abstract][Full Text] [Related]
9. Could urine testing be the future of cervical cancer screening?
Pathak N; Dodds J; Zamora J
Womens Health (Lond); 2015 Jun; 11(3):265-7. PubMed ID: 26102464
[No Abstract] [Full Text] [Related]
10. The role of human papillomavirus testing in cervical cancer screening.
Morasse L; Davidov A; Castellanos MR
JAAPA; 2009 Nov; 22(11):20-3. PubMed ID: 19999172
[No Abstract] [Full Text] [Related]
11. The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology.
Castle PE; Reid J; Dockter J; Getman D
J Clin Virol; 2015 Aug; 69():52-5. PubMed ID: 26209379
[TBL] [Abstract][Full Text] [Related]
12. Patient safety and the next generation of HPV DNA tests.
Lee SH
Am J Clin Pathol; 2011 Mar; 135(3):481; author reply 482-3. PubMed ID: 21350106
[No Abstract] [Full Text] [Related]
13. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?
Saraiya M; Berkowitz Z; Yabroff KR; Wideroff L; Kobrin S; Benard V
Arch Intern Med; 2010 Jun; 170(11):977-85. PubMed ID: 20548011
[TBL] [Abstract][Full Text] [Related]
14. Cervical cancer rates after the transition from annual Pap to 3-year HPV and Pap.
Dinkelspiel H; Fetterman B; Poitras N; Kinney W; Cox JT; Lorey T; Castle PE
J Low Genit Tract Dis; 2014 Jan; 18(1):57-60. PubMed ID: 24022057
[TBL] [Abstract][Full Text] [Related]
15. Clinical validation of REALQUALITY RQ-HPV Screen according to the international guidelines for human papillomavirus DNA test requirements for cervical screening.
Iacobellis M; Violante C; Notarachille G; Simone A; Scarfì R; Giuffrè G
Virol J; 2018 Mar; 15(1):48. PubMed ID: 29558950
[TBL] [Abstract][Full Text] [Related]
16. Glandular Lesions of the Cervix in Clinical Practice: A Cytology, Histology, and Human Papillomavirus Correlation Study From 2 Institutions.
Miller RA; Mody DR; Tams KC; Thrall MJ
Arch Pathol Lab Med; 2015 Nov; 139(11):1431-6. PubMed ID: 25951104
[TBL] [Abstract][Full Text] [Related]
17. Rightsizing cervical cancer screening: comment on "Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone".
Sawaya GF
Arch Intern Med; 2010 Jun; 170(11):985-6. PubMed ID: 20548012
[No Abstract] [Full Text] [Related]
18. Comparison of single-, double- and triple-combined testing, including Pap test, HPV DNA test and cervicography, as screening methods for the detection of uterine cervical cancer.
Kim JH; Kim IW; Kim YW; Park DC; Kim YW; Lee KH; Ahn TG; Han SJ; Ahn WS
Oncol Rep; 2013 Apr; 29(4):1645-51. PubMed ID: 23443346
[TBL] [Abstract][Full Text] [Related]
19. Commentary on statement on human papillomavirus test utilization.
Cox JT; Moriarty AT; Castle PE
Arch Pathol Lab Med; 2009 Aug; 133(8):1192-4. PubMed ID: 19653706
[No Abstract] [Full Text] [Related]
20. Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening.
Akbari A; Vanden Broeck D; Benoy I; Padalko E; Bogers J; Arbyn M
Virol J; 2018 Oct; 15(1):166. PubMed ID: 30373616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
